Hedgehog Signaling Pathway Inhibitors in the Treatment of Basal Cell Carcinoma: An Updated Review

The authors summarize basal cell carcinoma’s (BCC’s) clinical presentation and histopathology and present knowledge on the most studied Hh signaling inhibitors, vismodegib and sonidegib, and other inhibitors of this signalling, such as itraconazole, patidegib, taladegib, and arsenic trioxide, in the treatment of BCC.